Takeda: Pipeline, Products, Performance, Potential

Table of Contents

Latest Results

EXECUTIVE SUMMARY

• Introduction
• Financial Performance 2005
  • Sales and Market Position
  • Income
  • Expenditure
    • Capital Expenditure
    • Capital Expenditure By Business Area
    • R&D Expenditure
  • Divisional Performance
    • Sales By Business Area
    • Operating Income By Business Area
    • Total Assets By Business Area
  • Geographic Performance
    • Sales By Destination
    • Sales By Origin
    • Operating Income By Origin
    • Ethical Sales (In-House) By Geographic Region
• Company Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
  • Production
  • Employees
• Product/R&D Overview
  • Key Products
    • Recent Product Launches
    • Recent Product Approvals
  • R&D Strategy
    • Key R&D projects
    • Discontinued R&D projects
    • Discontinued Agreements
  • Sales Forecast
• Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

• Major Products, Therapeutic Areas and Sales
• R&D Pipeline

• Metabolic - Products
  • Major Launched Products
  • Actos
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Generic Competition/Lawsuits
    • Competitor Products
    • Sales Forecast
    • Clinical Trial Results
  • Basen
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Sales Forecast
• Metabolic - R&D
  • Cetilistat
    • Clinical Trial Results
  • SYR-322
  • TAK-654
• Metabolic - Summary
  • Growth Potential
  • Limiting Factors
• Gastrointestinal - Products
  • Major Launched Products
  • Takepron/Prevacid/Zoton
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Patents/Licensees
    • Competitor Products
    • Generic Competition
    • Sales Forecast
  • Altat
• Gastrointestinal - R&D
  • Lubiprostone/SPI-0211
  • TAK-390MR
  • Ilaprazole
• Gastrointestinal - Summary
• Cardiovascular - Products
  • Major Launched Products
  • Blopress
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Sales Forecast
    • Clinical Trial Results - Diabetic Retinopathy
    • Clinical Trial Results - Heart Failure
  • Adecut
  • Calslot
• Cardiovascular - R&D
  • Caldaret (MCC-135)
  • TAK-475
  • TAK-536
• Cardiovascular - Summary
  • Growth Potential
  • Limiting Factors
• Anticancer - Products
  • Major Launched Products
  • Isovorin
    • Sales
    • Sales Forecast
  • Leuplin/Lupron/Enantone
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Lawsuits
    • Patents
    • Competitor Products
    • Sales Forecast
  • Canferon A
  • Celeuk 40
  • Morphine hydrochloride
• Anticancer - R&D
  • Matuzumab/EMD 72000
  • TAK-165
  • Tavocept
• Anticancer - Summary
  • Growth Potential
  • Limiting Factors
• Musculoskeletal - Products
  • Major Launched Products
  • Benet
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Sales Forecast
  • Seltouch
    • Sales Forecast
  • Enbrel
  • Osten
• Musculoskeletal - R&D
  • Febuxostat
    • Clinical Trial
  • TAK-715
• Musculoskeletal - Summary
• Anti-infective - Products
  • Major Launched Products
  • Pansporin
    • Sales
    • Key Markets/Indications/Launches
    • Competitor Products
    • Sales Forecast
  • Firstcin
  • Others
• Anti-infective - R&D
  • R851
  • TAK-187
  • TAK-220
  • TAK-242
• Anti-infective - Summary
• Central Nervous System - Products
  • Rozerem
    • Further Development
    • Clinical Trial Results
• Central Nervous System - R&D
  • Ruboxistaurin (LY333531)
  • TAK-128
  • TAK-147
  • TAK-428
• Central Nervous System - Summary
• Other - Products
  • Dasen
  • Prostal
  • Solfa
  • TMR
  • Uprima/Ixense
    • Key Markets/Indications/Formulations
    • Further Development
• Other - R&D
  • Hematide
  • TAK-363

APPENDIX 1 - FINANCIAL PERFORMANCE

• Full Year Results 2005

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

• 3M Pharmaceuticals
  • 1st March 2005
• Abbott
  • 7th March 2000
  • 20th December 2005
• Affymax Inc
  • 13th February 2006
• Alizyme plc
  • 8th August 2003
  • 30th January 2004
• Andrx Corporation
  • 29th December 2003
• ASKA Pharmaceutical, KI Pharma
• 16th March 2006
• Cerexa Pharmaceuticals Inc
  • 30th September 2003
  • 19th October 2005
• Eli Lilly
  • 25th August 1999
  • 18th December 2003
• Evotec
  • 6th December 2005
• IL YANG Pharmaceutical Ltd
  • 9th September 2005
• Kissei Pharmaceutical Co Ltd
  • 5th August 2002
  • 11th May 2004
• Ligand Pharmaceuticals Inc
  • 28th December 2004
• Merck KGaA
  • 29th September 2005
• Mitsubishi Pharma Corporation
  • 31st July 2001
• Paradigm Therapeutics Ltd
  • 30th June 2005
• PPD Inc
  • 13th July 2005
• Pronova Biocare AS
  • 2nd November 2005
• Santhera Pharmaceuticals AG
  • 3rd August 2005
  • 15th December 2005
• Schering AG
  • 12th October 2005
• Sucampo Pharmaceuticals Inc
  • 1st November 2004
  • 31st March 2005
• Teijin Limited
  • 6th October 1999
• Toray Industries Ltd
  • 7th April 2005
• Licensing

APPENDIX 4 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES

• Subsidiaries
• Joint-Venture Companies

APPENDIX 6 - PRODUCT INDEX